Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CALC

CalciMedica Q2 2026 Earnings Report

CalciMedica logo
$0.46 -0.01 (-1.19%)
As of 08/28/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

CalciMedica EPS Results

Actual EPS
-$0.45
Consensus EPS
-$0.29
Beat/Miss
Missed by -$0.17
One Year Ago EPS
N/A

CalciMedica Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CalciMedica Announcement Details

Quarter
Q2 2026
Date
8/11/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

CalciMedica's next earnings date is estimated for Wednesday, November 11, 2026, based on past reporting schedules.

Conference Call Resources

CalciMedica Earnings Headlines

CalciMedica Announces 1-for-5 Reverse Stock Split
August 27 at 6:56 PM  |  rttnews.comhttps://www.rttnews.com/3685726/calcimedica-announces-1-for-5-reverse-stock-split.aspx
CalciMedica Announces One-for-Five Reverse Stock Split
August 27 at 9:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352053/0/en/calcimedica-announces-one-for-five-reverse-stock-split.html
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
August 29 at 1:00 AM  |  Porter & Company (Ad)
CalciMedica Inc. (NASDAQ:CALC) Receives $10.00 Average PT from Analysts
August 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30981902
CalciMedica (NASDAQ:CALC) Upgraded by Wall Street Zen to "Sell" Rating
August 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30975175
CalciMedica stock gains 6% as pulmonary hypertension progress offsets Q2 earnings miss
August 11, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/calcimedica-stock-gains-6-as-pulmonary-hypertension-progress-offsets-q2-earnings-miss/ar-AA29R86c
See More CalciMedica Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email.

About CalciMedica

CalciMedica (NASDAQ:CALC), Inc. (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia. Early-phase data suggest that CRAC channel inhibition can reduce inflammatory cytokine release and support organ function in critically ill patients.

CalciMedica pursues a development strategy that combines rigorous clinical evaluation with strategic collaborations to expedite potential regulatory approvals and commercialization. Operating primarily in the United States, the company works closely with academic centers and healthcare organizations to advance its pipeline. By targeting calcium signaling in innate immune cells, CalciMedica aims to fill unmet medical needs in acute inflammatory diseases and improve outcomes for high-risk patient populations.

View CalciMedica Profile
Earnings Tools